Augmenting Function for Infarction from Infection: Impella 2.5 for Ischemic Cardiogenic Shock Complicating Sepsis

Area of Science:

• Cardiology
• Critical Care Medicine
• Biomedical Engineering

Background:

• Sepsis frequently causes cardiac dysfunction, especially in patients with coronary artery disease (CAD), leading to poor prognoses.
• Severe cases can progress to ischemic cardiogenic shock, where medical therapy alone is often insufficient.
• Vasopressors and inotropes may increase myocardial demand, potentially worsening injury in this vulnerable population.

Observation:

• A patient with profound anemia and CAD presented with combined distributive and cardiogenic shock.
• The shock was complicated by a type 2 myocardial infarction secondary to sepsis.
• The patient was not a suitable candidate for immediate revascularization.

Findings:

• Percutaneous ventricular assist devices (PVADs) offer a viable management strategy for severe shock and multiorgan failure.
• The Impella 2.5, a novel mechanical support system, was successfully utilized.
• This device effectively augmented cardiac output while reducing myocardial oxygen demand.

Implications:

• Mechanical circulatory support, such as the Impella 2.5, can serve as a crucial bridge to recovery in severe hemodynamic compromise.
• This approach may be particularly beneficial for patients with complex comorbidities like anemia and CAD.
• Successful Impella use demonstrates its potential in managing sepsis-induced cardiogenic shock when conventional therapies fail.